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Summary: A number of clinical trials that test the efficacy 
and safety of the newer antiepileptic drugs (AEDs) have re- 
cently been concluded. Two dose-response trials in inpatients 
with refractory partial seizures and outpatients with newly di- 
agnosed partial epilepsy established the efficacy of gabapentin 
as monotherapy. Lamotrigine was found to have efficacy simi- 
lar to that of phenytoin and carbamazepine (CBZ) and to be 
better tolerated than CBZ in patients with newly diagnosed 
epilepsy. It was also shown to have efficacy as monotherapy in 
partial seizures, based on the results of an active controlled 
trial, and in the treatment of absence seizures, based on the 
results of a responder-enriched study. Topiramate as mono- 
therapy was found to be efficacious for treatment of partial- 
onset seizures, based on the results of a single-center dose- 
response trial. A dose-response trial that tested the efficacy of 
tiagabine monotherapy in patients with refractory partial epi- 
lepsy was uninformative. Oxcarbazepine was found to be safe 
and efficacious in four comparative trials in patients with newly 
diagnosed epilepsy as well as in one placebo-controlled inpa- 
tient trial in patients with refractory partial seizures. Key 
Words: Epilepsy--Clinical trials-Monotherapy-Antiepilep- 
tic drugs-Double-blind trials. 
Antiepileptic drugs (AEDs) administered as mono- 
therapy are the preferred treatment regimen for most pa- 
tients with epilepsy. Monotherapy offers several advan- 
tages over polytherapy, including avoidance of drug in- 
teractions, fewer adverse effects, greater ease of 
administration, and decreased cost. The more recently 
available AEDs, such as gabapentin (GBP), lamotrigine 
(LTG), and topiramate (TPM), are presently approved by 
the Food and Drug Administration (FDA) as add-on 
therapy for treatment of partial-onset seizures. Compared 
with the standard AEDs, these newer AEDs offer more 
favorable pharmacokinetic profiles, better tolerability, or 
both, and may prove useful when used as monotherapy. 
This article reviews the results of completed randomized, 
double-blind monotherapy trials with the newer AEDs, 
on the basis of published and as yet unpublished data. 
ADJUNCTIVE CLINICAL TRIAL DESIGNS 
The safety and efficacy of the newer AEDs were as- 
sessed initially in add-on clinical trials of relatively uni- 
form design. The typical protocol includes a baseline 
evaluation period of 8-12 weeks, followed by random- 
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ization of patients with refractory partial seizures in 
double-blind fashion to add-on treatment with either the 
study drug or placebo in addition to normal dosages of 
their baseline AEDs. The duration of the double-blind 
phase is 8-12 weeks and the primary efficacy variable is 
the reduction in seizure frequency, relative to baseline, 
demonstrated by the study drug and placebo. 
Although add-on trials offer some advantages, they 
also have a number of drawbacks. On the positive side, 
they have demonstrated efficacy for GBP, LTG, TPM 
(1 ), tiagabine (TGB), felbamate, and vigabatrin (2). Add- 
on trials are also considered ethical trial designs, in that 
participants who are randomized to the placebo arm con- 
tinue to take the same dosage of their baseline drugs. On 
the negative side is the tendency to overestimate adverse 
events (AEs) and to underdose the study drug. In addi- 
tion, there is always the concern of potential pharmaco- 
kinetic interactions between the study drug and the base- 
line AEDs. For example, if an add-on study drug causes 
an increase in the serum levels of baseline AEDs, deter- 
mining how much of the change in seizure frequency 
could be attributed to the study drug (as opposed to the 
contribution from elevated baseline AED serum levels) 
would be difficult. Conversely, the efficacy of a study 
drug that decreases the serum levels of baseline AEDs 
would tend to be underestimated in such a trial design 
(3). It is understandably difficult to predict from add-on 
trials the utility of the study drug in monotherapy be- 
cause, even in the absence of pharmacokinetic interac- 
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tions, the possibility of pharmacodynamic interactions 
between the study drug and the baseline AEDs always 
exists. For this reason, such trials support approval only 
for adjunctive indications. 
MONOTHERAPY TRIALS 
To obtain a monotherapy indication, a study drug 
should have demonstrated safety and efficacy in a mono- 
therapy trial. The requirements of regulatory agencies 
often dictate the designs of such clinical trials. As dis- 
cussed by Chadwick elsewhere in this supplement (4), 
the FDA and European regulatory agencies differ philo- 
sophically over the design and interpretation of mono- 
therapy trials. In  Europe, the most common monotherapy 
design is a comparative trial in which the safety and 
efficacy of a study drug is compared with that of a stan- 
dard AED that is believed to be effective for treating the 
seizure type(s) under evaluation. Although these trials 
most often fail to show a significant difference in effi- 
cacy between the study drug and the standard AED, Eu- 
ropean regulatory agencies accept the results of such 
trials as proof of efficacy of the study drug. The FDA, 
however, is suspicious of the validity of equivalence tri- 
als and doubts the efficacy of the study drug in such trial 
designs. Its rationale is often misunderstood and misrep- 
resented. The fundamental reason behind the FDA’s po- 
sition is that to accept the results of equivalence trials as 
proof of a study drug’s efficacy, it must assume that the 
comparative standard AED has efficacy in every patient 
population in which it is being tested and in all designs 
and dosages chosen (5,6). That is a precarious assump- 
tion, mainly because the.efficacy of most standard AEDs 
as monotherapy has never been established in placebo- 
controlled clinical trials. To satisfy the FDA require- 
ments for efficacy, it is therefore necessary to demon- 
strate the statistical superiority of the study drug in one 
arm of a trial against another. A number of designs, 
known as therapeutic failure designs (4), have been ad- 
vocated to satisfy these requirements for efficacy while 
maintaining patient safety. Although it is true that the 
designs and efficacy variables evaluated in these clinical 
trials do not provide much in  terms of clinically relevant 
data, they are the only trials that can definitely prove the 
efficacy of the study drug when it is used as mono- 
therapy. The results of specific studies involving the 
newer AEDs are summarized here. 
GBP MONOTHERAPY TRIALS 
GBP is presently indicated for adjunctive treatment of 
partial seizures in patients 12 years of age, on the basis 
of three double-blind, multicenter, placebo-controlled 
trials. These studies showed that addition of GBP to stan- 
dard AEDs at daily dosages of 600-1,800 mg signifi- 
cantly reduced the frequency of partial seizures (7-9). 
The efficacy and safety of GBP as monotherapy have 
been evaluated in three randomized, double-blind clini- 
cal trials conducted in the United States, Canada, and 
Europe. The North American trials consisted of outpa- 
tient and inpatient dose-response therapeutic failure de- 
signs in patients with refractory localization-related epi- 
lepsy. The European trial was an outpatient dose- 
response study of patients with newly diagnosed epilepsy 
(Table 1). 
Outpatient trial in patients with refractory 
partial seizures 
A 26-week, multicenter, double-blind, parallel-group, 
dose-controlled trial (Study No. 945-82) was undertaken 
to evaluate the safety and efficacy of GBP monotherapy 
in patients with medically refractory partial epilepsy 
(lo). The patients recruited for the study were 3 1 2  years 
of age and had experienced at least two complex partial 
or secondarily generalized tonic-clonic seizures (“study 
seizures”) per month while maintained on constant dos- 
ages of one or two standard AEDs. After an 8-week 
baseline period, qualified patients were randomized to 
treatment with GBP at 600, 1,200, or 2,400 mg daily, 
administered in three equally divided doses. Titration to 
the targeted dosage was carried out over 2 weeks, fol- 
lowed by an 8-week period during which the baseline 
AED(s) was tapered and discontinued (Fig. I ) .  Patients 
were then maintained on GBP monotherapy for a total of 
16 weeks or until they met one or more of the following 
protocol-defined exit events: a doubling of the 28-day or 
highest 2-day study seizure rate during baseline; a sec- 
ondarily generalized tonic-clonic seizure if none was 
experienced in the previous 2 years; an episode of status 
epilepticus; or a clinically significant intensification in 
seizure frequency or duration. The primary efficacy vari- 
able was time to exit from the double-blind phase. 
A total of 274 patients were randomized at 25 centers 
in the United States and Canada. Mean time to exit was 




Drug Comparative Inpatient Refractory New onset 
GBP 1 1 1 
LTG” 2 1 
OCBZ 4 1 
TGB 1 
TPM 1 
GBP, gabapentin; LTG, lamotrigine; OCBZ, oxcarbazepine; TGB, 
‘’ Also evaluated for treatment of new-onset absence seizures in one 
tiagabine; TPM, topiramate. 
placebo-controlled trial. 
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FIG. 1. Gabapentin (GBP) monotherapy outpatient study design. AED, antiepileptic drug. 
89-10 1 days, with no statistically significant difference 
across the three dosage groups. Kaplan-Meier estimates 
of time to exit showed that patients who were maintained 
on one AED during baseline and those whose baseline 
AEDs did not include carbamazepine (CBZ) remained 
longer in the study. The trough GBP plasma concentra- 
tion averaged approximately 2.5 mgL in  the 600-mg/day 
and 6 mg/L in the 2,400-mg/day dosage groups. GBP 
was well tolerated, with only 3% of patients exiting be- 
cause of significant side effects. The most common ad- 
verse events were dizziness ( 1  3-25%), somnolence (7- 
16%), headache (lO-l3%). ataxia (7-13%), and fatigue 
(614%). 
Inpatient trial in patients with refractory 
partial seizures 
This multicenter, double-blind, dose-response trial 
(Study No. 945-88) was performed in an inpatient set- 
ting. Patients who were enrolled had medically refractory 
partial epilepsy, were admitted for EEG monitoring via 
closed-circuit television, and had discontinued their base- 
line AEDs as part of their surgical workup (1 1). Quali- 
fying patients were randomized to treatment with GBP at 
300 mglday or 3,600 mg/day, with the full daily dosage 
administered on day 1 on a t.i.d. schedule (Fig. 2). Pa- 
tients remained in  the trial for a total of 8 days or until 
they satisfied one of the following exit criteria: four com- 
plex partial or secondarily generalized tonic-clonic sei- 
zures; a single generalized tonic-clonic seizure if none 
had occurred during the previous 6 months; an episode of 
status epilepticus; or a significant prolongation in the 
duration or intensity of the seizures. The primary effi- 
cacy variable was time to exit between the two groups, 
and the secondary efficacy parameter was the percentage 
of patients in each group who completed the 8-day trial 
without satisfying any of the study-defined exit criteria. 
A total of 82 patients were randomized in the trial. The 
mean time to exit was significantly longer for patients 
receiving 3,600 mglday (151 h) than for patients receiv- 
ing 300 mg/day (85 h) (p = O.OOO1). Similarly, 53% of 
patients randomized to the high-dosage group completed 
the trial, compared with 17% of those randomized to the 
low-dosage group (p = 0.002). The mean trough GBP 
level in patients randomized to the 300-mg/day group 
was 1 mg/L compared with 9 mgL for those in the 
3,600-mg/day group. Despite administration of the full 
dose on day 1, none of the patients exited the trial be- 
cause of AEs. The most common AEs for patients in the 
3,600-mg/day group were ataxia (20%), dizziness (1 8%), 
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FIG. 2. Gabapentin (GBP) monotherapy inpatient 
study design. AED, antiepileptic drug. 
Day 1 Day2 
GBP dose initiation 
Lorazcpam coverage 
Seizure counting toward exit criteria begins 
somnolence (15%), nystagmus (13%), paresthesia 
(lo%), and fatigue (10%). 
Outpatient trial in patients with new-onset seizures 
In a multicenter, randomized, double-blind, dose- 
response clinical trial, 292 patients with newly diagnosed 
epilepsy who had experienced at least two partial or gen- 
eralized tonic-clonic seizures were randomized to 
blinded dosages of GBP (300,900, or 1,800 mglday) or 
to open-label treatment with CBZ at 600 mg/day (Fig. 3). 
After a titration period (1 week for GBP, 3 weeks for 
CBZ), patients were maintained on randomized dosages 
for 24 weeks or until they experienced one or more exit 
events, defined as one generalized tonic-clonic seizure, 
three partial seizures, status epilepticus, or other lack of 
efficacy. The primary efficacy variable was time to exit 
across the three blinded GBP dosage groups. 
Mean time to exit was significantly longer for patients 
who received GBP 900 mg/day (p = 0.02) or 1,800 
mg/day (p = 0.04) than for patients who received 300 
FIG. 3. Gabapentin (GBP) monotherapy 
new-onset epilepsy study design. CBZ, 
carbarnazepine. 
End of day 8 
or met exit 
criteria 
mg/day. The exit rate was significantly higher for the 
GBP group receiving 300 mglday than for those in the 
900-mg/day (p = 0.01) or 1,800-mg/day (p = 0.02) 
dosage groups. No significant difference was found in 
time to exit or exit rate between the GBP 900-mg/day 
and 1,800-mglday groups. The withdrawal rate attribut- 
able to AEs was significantly higher for the GBP 1,800 
mglday group than for the GBP 300-mglday group (p = 
0.003). Time to exit and completer rates were compa- 
rable for patients treated with CBZ and for those treated 
with GBP at 900 mg/day or 1,800 mg/day. The exit rates 
were 30,40, and 43% in the CBZ, GBP 900-mg/day, and 
GBP 1,800-mglday groups, respectively, whereas the 
withdrawal rates attributable to AEs were 24.4, and 14% 
in the same groups, respectively. 
LTG MONOTHERAPY TRIALS 
In the United States, LTG has been approved as an 
add-on agent for treatment of partial seizures in patients 
I '. Y I 
Day 1 
I 
HMbdCd Titration Evaluation Extended GBP dose Protocol 945-078 
screening GBP (lwk) (24 wk) treatment conversion Open-label long- 
period (6 mo) CBZ (3 wk) evaluation (3 days) term treatment 
period I l n c r d J - I m m l )  
(.11Mm.l1 rk) 
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aged 2 16 years on the basis of results of clinical trials in 
which daily dosages of 300-500 mg were used ( 1  3,14). 
The efficacy and safety of LTG as monotherapy have 
been evaluated in two European comparative trials in 
patients with newly diagnosed epilepsy and in one North 
American active-control, therapeutic failure design trial 
in  patients with medically refractory partial seizures 
(Table 1). 
Comparative trial of LTG vs. CBZ 
This 48-week study was a multicenter, double-blind, 
parallel-group design clinical trial that compared the ef- 
ficacy and safety of LTG with that of CBZ in patients 
2 13 years of age who had newly diagnosed, untreated 
epilepsy and were naive to AED treatment ( 1  5). LTG and 
CBZ were titrated over a 4-week period to a total daily 
dosage of 150 mg for LTG and 600 mg for CBZ on a 
b i d .  schedule. During weeks 6-24, dosage adjustments 
were permitted on the basis of seizure occurrence, AEs, 
and serum levels. Between weeks 25 and 48, the daily 
dosage remained constant except when adverse events 
required decreasing the dose. Efficacy variables were 
time to first seizure after 6 weeks of treatment, time to 
withdrawal, and proportion of seizure-free patients dur- 
ing the last 24 and last 40 weeks of the trial. 
A total of 260 patients were randomized at eight cen- 
ters throughout the United Kingdom. Approximately 
55% of patients in each group had partial seizures with or 
without secondary generalization, whereas the rest had 
primary generalized epilepsy with tonic-clonic seizures. 
No statistically significant difference was found between 
the two groups (or according to seizure types in each 
group) either in time to first seizure after 6 weeks of 
treatment or in the percentage of seizure-free patients 
during the last 24 weeks (39% LTG, 38% CBZ) or 40 
weeks (26% LTG, 29% CBZ) of treatment. The median 
daily dosage of LTG was 150 mg (range 100-300 mg), 
with median serum levels ranging between 2.6 and 3.2 
m g L  The median daily dosage of CBZ was 600 mg 
(range 300-1,400 mg), with median serum levels ranging 
between 7.4 and 8.3 mg/L. Time to withdrawal analysis, 
a measure of both efficacy and tolerability, showed that 
significantly more patients in the LTG group completed 
the trial compared with the CBZ-treated group (65% vs. 
51%; p = 0.018). A total of 35 CBZ-treated patients 
(27%) exited the trial because of AEs, compared with 19 
patients (15%) who had been treated with LTG. Rash 
was the most common AE leading to withdrawal from 
the study in  both groups. Sleepiness or ataxia led eight 
CBZ-treated patients to exit the trial, compared with 
none in the LTG-treated group. Overall, the most com- 
mon AEs were headache (LTG group 30%; CBZ group 
25%), asthenia (LTG group 21%; CBZ group 29%), and 
rash (19% in each group). No statistically significant 
differences were found between the two groups with re- 
spect to frequency of AEs except for sleepiness, which 
was seen in 22% of CBZ-treated patients compared with 
12% of LTG-treated patients (p < 0.05). 
Comparative trial of LTG vs. phenytoin (PHT) in 
newly diagnosed epilepsy 
In a multicenter, double-blind, parallel-group, concen- 
tration-controlled clinical trial, 18 1 patients aged 14-75 
years with newly diagnosed untreated epilepsy were ran- 
domized to treatment with LTG or PHT (16). Efficacy 
variables were time to first seizure after 6 weeks of treat- 
ment, time to withdrawal, and proportion of patients who 
were seizure-free during the last 24 weeks of the trial. 
No significant difference was found between the two 
groups in time to first seizure after 6 weeks of treatment, 
percentage of seizure-free patients during the last 24 
weeks of treatment (43% LTG and 36% PHT), or in time 
to exit from the study. Modal dosages during the study 
were 150 mglday for LTG- and 300 mglday for PHT- 
treated patients. 
Outpatient trial in patients with medically 
refractory epilepsy 
A 156-patient, multicenter, double-blind, parallel- 
group, active-contrd study was conducted at 36 centers 
across the United States (17). The participants were 
medically refractory patients 3 13 years of age who had 
experienced eight or more partial seizures during an 8- 
week baseline period while maintained on PHT or CBZ 
monotherapy, and were randomized to treatment with 
LTG 500 mg/day or valproate (VPA) 1,000 mg/day. 
Conversion took place over a period of 8 weeks, after 
which the patients were maintained on randomized doses 
as monotherapy for 12 weeks or until they satisfied one 
or more of the following exit criteria: a doubling of the 
28-day or highest 2-day seizure frequency during base- 
line; emergence of a new and more severe seizure type; 
or significant prolongation of generalized tonic-clonic 
seizures (Fig. 4). The primary efficacy variable was the 
proportion of patients who met exit criteria, and the sec- 
ondary outcome parameter was time to exit across the 
two treatment groups. 
The proportion of treatment failures in the LTG group 
was 63%, compared with 84% for patients randomized to 
the VPA group (p < 0.007). The median time to treat- 
ment failure was significantly longer in the LTG-treated 
patients (80 days) vs. the VPA-treated patients (58 days) 
(p = 0.027). Overall, LTG was well tolerated in this 
trial. 
LTG monotherapy and absence seizures 
The safety and efficacy of LTG monotherapy for ab- 
sence seizures were evaluated in a multicenter, double- 
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FIG. 4. Lamotrigine (LTG) monotherapy active-control study design. CBZ, carbamazepine; PHT, phenytoin; VPA, valproate. 
blind, responder-enriched study in children and adoles- 
cents aged 2-16 years with newly diagnosed typical ab- 
sence seizures who were naive to AED treatment (18). 
The diagnosis of absence seizures was confirmed by 
EEG recording during hyperventilation. After enrollment 
in the trial, all patients received LTG during a 4- to 
18-week open-label treatment phase. The initial LTG 
dosage, 0.5 mg/kg/day for the first 2 weeks, was pro- 
gressively increased (by 0.5 mg/kg/day for the subse- 
quent 2 weeks, then by 1 mg/kg/day at weekly intervals) 
until the patients became seizure-free or reached the 
maximal allowable LTG dose: the lesser of 7 mg/kg/day 
or 700 mg/day for the first 20 patients, and the lesser of 
15 mg/kg/day or 1,OOO mg/day for the subsequent 25 
patients (Fig. 5). Patients who became seizure-free were 
assigned in a 1:1 ratio during the double-blind phase to 
either placebo treatment after LTG taper or continuation 
of the LTG dose determined to be effective during the 
open-label phase. If patients developed seizures at any 
time during the 4-week double-blind phase, they were 
considered to have completed the study. The primary 
efficacy variable was the proportion of patients in each 
treatment group who remained seizure-free throughout 
the double-blind treatment phase. 
Of the 45 patients enrolled in the open-label treatment 
phase, 28 patients were randomized in the double-blind 
phase. Significantly more patients in the LTG group 
remained seizure-free throughout the double-blind phase 
(64%) compared with patients in the placebo group 
(36%) (p c 0.05). In the open-label treatment phase, 
71% became seizure-free receiving a mean LTG dose 
of 6 mg/kg/day (range 2-15 mg/kg/day). LTG was 




FIG. 5. Lamotrigine (LTG) monotherapy new-onset absence seizure study design. 
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TPM MONOTHERAPY TRIAL 
TPM monotherapy for medically refractory partial sei- 
zures was evaluated in a single-center, double-blind, 
dose-response, therapeutic-failure design clinical trial 
(19). The patients enrolled in the trial had four or more 
partial-onset seizures per month while maintained on 
constant doses of one or two AEDs during a 56-day 
baseline phase. After 1 week of open-label add-on TPM 
at 100 mg/day, study participants were randomized to 
receive either 100 mg/day or 1,000 mg/day of TPM taken 
on a b i d .  schedule (Fig. 6). The conversion to mono- 
therapy took place over 5 weeks, after which patients 
were maintained in randomized TPM dosage groups for 
11 weeks or until they satisfied one or more of the fol- 
lowing exit criteria: a doubling of the 28-day or highest 
2-day seizure frequency during baseline; a secondarily 
generalized tonic-clonic seizure (if none was noted dur- 
ing baseline); serial seizures or status epilepticus; or 
more prolonged duration of generalized seizures. The 
primary efficacy variable was time to exit between the 
two groups, and the secondary efficacy parameter was 
the percent completers across the two dosage groups. 
A total of 48 patients were randomized in this trial. 
Time to exit was significantly longer for patients receiv- 
ing 1,OOO mg/day than for those receiving 100 mg/day 
(p = 0.002). Similarly, 54% of patients randomized to the 
high-dosage group completed the trial, compared with 
17% randomized to the lower dosage group (p = 0.02). 
Only one patient discontinued the trial during the double- 
blind phase because of AEs. The most frequently re- 
ported AEs were paresthesias (56-63%), fatigue (33- 
46%). dizziness (25%), headache (25%), and nausea 
(17-25%), with similar incidence between the two 
groups except for anorexia, which was more common in 
the TPM 1,000 mg/day group. 
TGB MONOTHERAPY TRIAL 
The safety and efficacy of TGB as monotherapy were 
evaluated in patients with medically refractory partial 
seizures in a multicenter, double-blind, parallel-group, 
dose-response, therapeutic-failure-design clinical trial 
(20). Recruited patients ranged in age from 10 to 85 
years, and had experienced at least four complex partial 
seizures, with or without secondary generalization, over 
an 8-week period while maintained on constant doses of 
one AED. After an 8-week baseline period, patients were 
randomly assigned to treatment with TGB 6 mg/day or 
TGB 36 mg/day (Fig. 7). Patients were titrated to the 
target dosage over a 2-week period that was followed by 
a 4-week taper and discontinuation of the baseline AED. 
They were subsequently maintained in randomized dos- 
age groups for a total of 12 weeks or were eligible to exit 
if any of the following criteria were met: a secondarily 
generalized tonic-clonic seizure in patients if no previ- 
ous history of this seizure type had been noted; two 
generalized tonic-clonic seizures if none had occurred 
during baseline; and doubling of the highest 2-day sei- 
zure frequency during baseline. The primary efficacy 
variable was the median 4-week complex-partial seizure 
rates between the two dosage groups. 
A total of 198 patients from 22 centers across the 
United States were randomized in the trial. No statisti- 
cally significant difference was observed between the 
two groups in the median 4-week complex partial seizure 
rates, nor in time to exit. Trial completion was achieved 
by 34 patients (33%) in the 6-mglday group and 23 
Baseline phase Open-label phase Double-blind phase 
Conversion* Monotherapy 
TPM 1,OOO mg/day (n=24) 
TPM / 
1/3 decreases in AED dosage** 
TPM 1,OOO mg/day (n524) 
Randomization 
8 wks 1 wk 5 wk 11 wk 
FIG. 6. Topiramate (TPM) monotherapy study design (from ref. 19). 'Titration of TPM dosage; '"second subtherapeutic antiepileptic drug 
(AED), if any, discontinued on day 8. 
Epilepsia. Vol. 38, Suppl. 9, 1997 
S28 A. BEYDOUN 
Baseline period : Titration period j Fixed-dose period 
- : - I  
(8 wk) (6 wk) (12 wk) 
i 
Conversion to i 
36 mg TGB (n = 96) FIG. 7. Tiagabine (TGB) monotherapy 
study design. AED, antiepileptic drug. 
, .  I \  
------------------ Baseline AED i- monotherapy 
; '\\ 
'\ . ' i 6 mg TGB (n = 102) 
'\ '. '. : 
patients (24%) in the 36-mg/day group. A statistically 
significantly higher percentage of patients in the TGB 
36-mg/day group experienced amblyopia, dizziness, in- 
coordination, nervousness, paresthesias, somnolence, 
speech disorder, abnormal thinking, and tremor com- 
pared with patients in the TGB 6-mg/day group. 
OXCARBAZEPINE (OCBZ) 
MONOTHERAPY TRIALS 
The safety and efficacy of OCBZ monotherapy have 
been evaluated in four European comparative trials in 
patients with newly diagnosed epilepsy and in one North 
American inpatient therapeutic-failuredesign trial in pa- 
tients with medically refractory partial epilepsy. 
Comparative trials 
All four European trials had similar designs. Patients 
with partial seizures or with idiopathic generalized epi- 
lepsy with tonic-clonic seizures were randomized in a 
double-blind fashion to treatment with OCBZ or one of 
the standard AEDs. The trial consisted of an 8-week 
titration phase followed by a 48-week maintenance pe- 
riod. Efficacy variables consisted of the mean seizure 
frequency per week and the percentage of seizure-free 
patients during the maintenance phase. 
OCBZ was compared with PHT in adults aged 15-91 
years and in  children and adolescents aged 5-17 years. In 
both trials, PHT and OCBZ had similar efficacy, with 
57-65 of patients remaining seizure-free during the 
maintenance phase. However, OCBZ was significantly 
better tolerated than PHT in both trials, with withdrawal 
because of AEs being significantly less frequent in 
OCBZ-treated patients ( 2 4 % )  compared with PHT- 
treated patients ( 1  1-15%). The daily dosage of OCBZ 
averaged 672 mg in children and adolescents (range 
300-1,350 mg) and 1,028 mg (range 600-2,100 mg) in 
adults. The average daily PHT dosage was 226 mg 
(range 106400 mg) in children and adolescents and 313 
mg (range 100-650 mg) in adults. 
A comparative trial between OCBZ and VPA in 424 
patients aged 15-65 years found them to be of similar 
efficacy and tolerability, with 60% of patients random- 
ized to OCBZ remaining seizure-free during the mainte- 
nance phase compared with 57% of VPA-treated pa- 
tients. AEs led to withdrawal rates of 13% and 7% in 
OCBZ- and VPA-treated patients, respectively. The av- 
erage daily dosage of OCBZ was 1,052 mg (range 600- 
2,400 mg) and that of VPA was 1,146 mg (range 600- 
2,700 mg). 
Inpatient trial in patients with refractory 
partial seizures 
The efficacy and safety of OCBZ in monotherapy 
were evaluated in a multicenter, double-blind, random- 
ized, placebo-controlled inpatient trial whose study 
population consisted of patients undergoing evaluation 
for epilepsy surgery (2 1). Eligible patients were random- 
ized to receive OCBZ (1,200 mg b id . )  or placebo (Fig. 
8). Patients remained in the trial for 10 days or until they 
experienced one of the following study-defined exit cri- 
teria: a total of four seizures; two new-onset secondarily 
generalized seizures; serial seizures; or status epilepticus. 
The primary efficacy variable was time to exit between 
the two groups, and the secondary efficacy parameter 
was the percentage of patients who met one or more of 
the exit criteria. 
A total of 102 patients were randomized in this trial, 
with time to exit being significantly longer in OCBZ- 
treated patients compared with placebo (p = 0.001). Of 
the OCBZ-treated patients, 44% met an exit criterion 
compared with the placebo-treated patients, 88% of 
whom met an exit criterion (p < 0.001). 
THERAPEUTIC FAILURE DESIGN TRIALS 
The design of monotherapy trials in the United States 
is in an evolutionary stage, and much can be learned 
from the results of the concluded trials. For example, 
inpatient trials appear to be very useful for demonstrating 
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Screening phase 
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Double-blind phase (10 days) Extension phase (indefinite) 
Day 1=1500 mg OCBZ 
Day 2=2400 mg (2400 mg/day) 
~ 
Day 1 Day 2 End c day 10 
S2 9 
FIG. 8. Oxcarbazepine (OCBZ) monotherapy inpatient study design. 
the efficacy of a study drug as monotherapy in a rela- 
tively short period of time and with a relatively small 
number of patients. Thus far, all concluded trials that use 
this design (either dose-response or placebo-controlled) 
have resulted in “positive” trials (1 1,21,22). These stud- 
ies are conducted in a controlled environment, the sei- 
zure count is well documented, and the risk to patients is 
minimized by the inclusion of strict exit criteria. How- 
ever, this type of design does not provide any informa- 
tion about the long-term safety of the study drug as 
monotherapy or about its efficacy over time because of 
the development of tolerance. In addition, drugs that can- 
not be titrated quickly, such as LTG or TPM, cannot be 
tested in such a study design. On the other hand, mono- 
therapy trials in outpatients with medically refractory 
partial seizures are proving to be very difficult designs. 
Despite differences in the duration of the double-blind 
and conversion phases and in the allowed number of 
baseline AEDs, the completer rates have been uniformly 
low across all such concluded trials (Table 2). Although 
two of the four trials were “positive” and two were 
“uninformative” (9, the only study with a completer 
rate of greater than 50% was the single-center dose- 
response trial with TPM. Various factors that lead to a 
high failure rate may play a role in this type of design, 
including the refractory nature of the patient population 
being tested, the occurrence of withdrawal seizures, the 
duration of the trial, the dosages of the study drug cho- 
sen, and perhaps an incentive for some patients to be in 
the open-label phase of the trial. The trend toward this 
type of design is likely to continue and may prompt a 
shift toward testing of the efficacy of study.drugs as 
TABLE 2. Outpatient therapeutic-failure-design trials in patients with medically refractory 
partial epilepsy 
Duration 
of double- Duration of Baseline Completer 
Dosage Patients blind phase conversion AEDs rate 
Drug (mdday) (%) (wk) phase (wk) (4 (%) 
600 93 26 10 
GBP I.200 90 26 
2,400 91 26 (2 + 8) 
LTG LTG500 76 20 8 
VPA 1,000 80 20 (4 + 4) 
100 24 16 5 
I.000 24 16 5 
TPM 
6 I02 18 6 
36 96 18 (2 + 4) 
TGB 
I o r 2  
I o r 2  
I o r 2  
1 
I 
I o r 2  












AEDs, antiepileptic drugs; other abbreviations as in Table 1. 
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monotherapy in patients with less refractory seizures or 
in those with newly diagnosed epilepsy in future clinical 
trials. 
EFFICACY OF THE NEWER AEDs 
AS MONOTHERAPY 
Thus far, evaluation of GBP as monotherapy has con- 
sisted of three clinical trials: two “positive” and one 
uninformative (Table 3). Their results have been submit- 
ted to the FDA to satisfy requirements for efficacy. A 
supplemental new drug application for a monotherapy 
indication in patients with partial-onset seizures was 
filed in September of 1996, with a decision expected in 
the fall of 1997. The efficacy of LTG monotherapy was 
shown in one active-control trial in patients with medi- 
cally refractory partial epilepsy. In addition, its efficacy 
was found to be similar to that of PHT and CBZ and 
significantly better tolerated than CBZ (Table 2). On the 
basis of these trials, a supplemental new drug application 
for monotherapy indication was filed with the FDA in 
early 1997. It is likely that approval will be granted based 
on that one “positive” trial alone, because divalproex 
sodium was recently approved for monotherapy indica- 
tions based on the “positive” results of a single thera- 
peutic-faiiure-design clinical trial (23). OCBZ was found 
to have equivalent efficacy to and comparable or supe- 
rior tolerability than the standard AEDs. It was also 
shown to have short-term anticonvulsant properties as 
monotherapy in an inpatient trial (Table 3). The “posi- 
tive” results from the inpatient trial alone are unlikely to 
satisfy the FDA’s requirements, because information ob- 
tained solely from one or more short inpatient trials 
makes it difficult to approve a drug for an outpatient 
population. An interesting point for discussion would be 
whether the results of one or more “positive” inpatient 
trials, in conjunction with one or more comparative trials 
showing equivalence between the study drug and a stan- 
dard AED, should be enough to satisfy the FDA’s re- 
quirements for efficacy. TPM was found to have efficacy 
as monotherapy in a single-center, dose-response trial 
(Table 3) (24). Although these results are encouraging, 
more data are needed to establish the efficacy of TPM as 
monotherapy. The TGB trial yielded uninformative re- 
sults, and more studies are needed to evaluate its efficacy 
as monotherapy (Table 3) (25). 
TABLE 3. Therapeutic failure designs 
Comparative Active 
equivalence Presurgical control Dose-response 
GBP + + 
LTG Yes + 
TPM + 
OCBZ Yes + 
TGB - 
Abbreviations as in  Table I 
Eliilqisici. Vol.  38. Sujipl. 9. 1997 
CONCLUSIONS 
Although therapeutic-failure-design trials are the only 
types of trials that can unequivocally prove the efficacy 
of the study drug as monotherapy, they do not necessar- 
ily address the concerns of physicians about how the 
study drugs compare with more familiar standard AEDs, 
or how best to use them as monotherapy. It is unlikely 
that pharmaceutical companies will be willing to invest 
large sums of money to answer these questions once 
FDA approval has been granted for some indication. We 
are therefore left with trials that show statistical evidence 
of efficacy but whose clinical utility, especially when 
compared with the standard AEDs, remains largely un- 
determined. Concerns regarding the statistical validity of 
equivalence trials and the clinical relevance of therapeu- 
tic-failure-design trials remain unresolved. 
The answer need not be an eithedor phenomenon. The 
design of statistically sound and clinically relevant 
monotherapy trials will require input from regulatory 
agencies, statisticians, pharmaceutical companies, clini- 
cians, and insurance company representatives. In addi- 
tion, much can be learned from the results of completed 
monotherapy trials to design future studies that not only 
are statistically sound but are also safe and clinically 
relevant. 
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